A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder DRAGON

To evaluate the dose-response relationship of YM178-OCAS on efficacy in patients with OAB.